
Learn how symptoms, repeat morning tests, assay reliability and related biomarkers fit into a clinical assessment of testosterone deficiency.

Testosterone deficiency, also called hypogonadism, is a clinical condition in which low testosterone occurs alongside compatible symptoms or signs. For adult men being assessed for late-onset hypogonadism, diagnosis combines those clinical findings with consistently low testosterone measured under appropriate conditions.
This article is for informational purposes only and is not medical advice. Personal testing and treatment decisions belong with a qualified clinician.
Total testosterone is the initial blood measurement used in the assessment described by the EAU guideline on male hypogonadism. The guideline uses 12 nmol/L (3.5 ng/mL) as a reference threshold for late-onset hypogonadism. It recommends confirmation of results below that level and interpretation alongside the patient’s symptoms.
That threshold is a clinical decision point rather than a complete laboratory reference range. It should not be treated as a universal boundary that separates every healthy man from every man with hypogonadism. The EAU approach requires compatible symptoms or signs together with consistent biochemical findings.
Biologically, a low total-testosterone result provides evidence about the testosterone concentration in blood. It does not establish why the concentration is low. It also does not establish that testosterone explains a particular symptom.
The EAU reports variation in laboratory methods and reference ranges. It notes that commercial immunoassay ranges may have limitations related to their reference populations and the conditions before sampling. Those differences matter when someone compares results from different laboratories.
A laboratory flag and a clinical diagnosis therefore serve different purposes. The flag identifies a result relative to that laboratory’s reporting range. The clinical assessment asks whether the measurement is reliable and whether it fits the person’s symptoms and wider health picture.
For readers comparing several reports, understanding results alongside symptoms is more useful than choosing whichever reference interval gives the simplest answer.
The EAU recommends measuring total testosterone between 07:00 and 10:00, in a fasting state. Diagnosis requires low morning testosterone on at least two occasions. Confirmation is part of the assessment before testosterone therapy is considered.
Testing conditions can materially affect the result. The guideline reports that non-fasting measurements may underestimate total testosterone by more than 30% in some circumstances. That finding supports consistent sampling conditions; it is not a formula for adjusting an individual result after the fact.
Useful details to bring into the discussion include:
These details help a clinician judge how comparable the measurements are. Our explanation of why blood-draw timing affects interpretation provides further context for that part of the assessment.
An assay is the laboratory method used to measure a substance. The EAU identifies LC-MS/MS as the most accurate method for sex-steroid evaluation. It also notes that standardized automated immunoassays for total testosterone can correlate well with LC-MS/MS.
This distinction avoids an unnecessary all-or-nothing view of testing. The guideline does not say that every total-testosterone immunoassay is unsuitable. Instead, it emphasizes reliable measurement and recognizes that laboratory methods differ.
When reports appear inconsistent, the method and reference interval are relevant discussion points. They belong alongside sampling conditions rather than being treated as technical details with no clinical importance.
The EAU identifies sexual symptoms as more specific to hypogonadism than many other reported symptoms. These include:
The guideline also lists less-specific symptoms such as fatigue, low energy, sleep problems and concentration difficulties. These concerns can be important to the person experiencing them. Their presence alone does not identify testosterone deficiency as the cause.
The key limitation is that symptoms are not exclusive to hypogonadism. The EAU therefore places them within the broader clinical and biochemical assessment. A symptom checklist can organize a conversation but does not function as a diagnostic test.
A useful symptom account separates what someone has noticed from what they believe is causing it. “I have fewer morning erections” describes an observation. “My testosterone must be low” is an interpretation that still needs clinical assessment.
The same principle applies when symptoms and results appear to disagree. Persistent concerns deserve a discussion of the wider clinical picture rather than a search for a different cutoff that produces a preferred label. Testostra’s guide to the foundations of a reliable assessment explains how symptoms and repeated measurements fit together.
The EAU identifies several health and medication factors associated with changes in SHBG. These associations matter because the guideline recommends measuring SHBG and calculating free testosterone when SHBG is likely to be altered.
Factors associated with lower SHBG include:
Factors associated with higher SHBG include:
These factors give the clinician a reason to consider more than total testosterone alone. A medication and health history can help explain why additional measurements might be useful for one man but not another.
Food intake belongs in the sampling context described earlier. The guideline’s fasting recommendation concerns obtaining an interpretable measurement. It should not be confused with advice to select a particular food or supplement in response to a low result.
Free testosterone is an additional assessment that can clarify some total-testosterone findings when SHBG is altered. Under those circumstances, the EAU recommends SHBG measurement and free-testosterone calculation. This is a targeted use of related biomarkers rather than a requirement for every man to receive every available hormone test.
The method matters here as well. The guideline advises against direct free-testosterone immunoassays because they do not estimate free testosterone accurately. It identifies equilibrium dialysis as the most accurate measurement method.
The EAU also describes calculation as an alternative. That calculation uses:
A report labelled “free testosterone” therefore needs to be understood in terms of how the result was obtained. A calculated value and a direct immunoassay result should not automatically be treated as equivalent assessments.
The guideline says free-testosterone assessment can improve diagnostic accuracy in selected symptomatic men, particularly older men with obesity. However, it describes the evidence behind a proposed free-testosterone threshold as limited. Its useful role is to clarify the clinical picture rather than create another universal pass-or-fail number.
Once testosterone is found to be pathologically low, the assessment also turns toward the underlying cause. The EAU recommends measuring LH alongside prolactin in that setting. It describes LH and FSH as useful for distinguishing primary from secondary hypogonadism.
In broad terms, those categories address different parts of the hormone system:
LH and FSH help the clinician investigate which pattern may be present. Their purpose differs from that of repeat testosterone measurements: one part of the workup confirms the biochemical finding while another helps classify its origin.
This is why an expanded hormone panel needs an explanation of the question each test is intended to answer. More results are useful when they address a clinical question, not simply because they add numbers to a report.
The EAU also distinguishes functional hypogonadism from organic causes. Functional hypogonadism is associated with other health conditions or concomitant drugs. The guideline characterizes it as a diagnosis of exclusion after organic causes have been ruled out.
That distinction prevents a contributing condition from becoming an automatic explanation. Finding obesity or a relevant medication does not finish the investigation by itself. The clinician still has to consider the full pattern of symptoms and hormone findings.
For the patient, the practical goal is to understand what the available results establish and which questions remain open. That keeps the discussion focused on the reason for further assessment rather than on assembling the largest possible panel.
Ask your physician: “Do my symptoms fit testosterone deficiency? Were my testosterone measurements taken under suitable morning and fasting conditions? Does the low result need confirmation? How do the assay and laboratory range affect interpretation? Would SHBG and calculated free testosterone clarify my findings? Would LH or FSH help investigate the cause?”
Testosterone-deficiency workups sit with the clinician responsible for assessment, while Testostra helps readers understand the terminology rather than manage their own hormone care. Its evidence-led coverage explains how total testosterone relates to free testosterone and SHBG, helping men turn confusing biomarker reports into better-informed questions without presenting general education as an individual diagnosis.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra